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Background
Cardiac magnetic resonance (CMR) stress perfusion imag-
ing with either adenosine or dipyridamole is increasingly
used both in clinical and research practice. In nuclear Car-
diology, the safety of adenosine stress has been confirmed
in large-scale studies, although the data is more limited in
the CMR setting. In theory, use of these stress agents in the
CMR environment might be more risky due to the
reduced robustness of ECG monitoring and the need for
remote resuscitation in case of emergency, especially for
patients with high likelihood of significant coronary
artery disease (CAD). In this study, we sought to deter-
mine the safety and tolerability of adenosine stress CMR
in patients with CAD.
Methods
We retrospectively examined all adenosine CMR per-
fusion scans performed in our centre between May 2003
and September 2007 in patients with suspected or docu-
mented CAD. These comprised both clinical and research
scans, and were undertaken at either 1.5 Tesla (Sonata,
Siemens Medical Solutions, Erlangen, Germany; n = 160)
or 3 Tesla (Trio, Siemens Medical Solutions; n = 152). All
subjects were screened for the presence of contraindica-
tions to adenosine (asthma, significant conduction
abnormalities greater than first degree atrioventricular
node [AV] block), and an ECG was performed prior to the
scan. Information on safety and adverse events during and
after adenosine infusion were routinely recorded, together
with haemodynamic data. The dose of adenosine infused
was 140 μg/kg/min for all subjects. Safety precautions
included the provision of resuscitation facilities with
availability of aminophylline and glyceryl trinitrate. All
scans were undertaken by staff familiar with and trained
in the evacuation and resuscitation protocols of the unit.
Significant CAD was defined angiographically as the pres-
ence of at least one stenosis of > 50% diameter.
Results
Data were collected from 312 consecutive subjects (mean
age 62 ± 11 years, range 25–85 years-219 men). Of the
312 subjects, 280 had a coronary angiogram (the remain-
ing 32 subjects were normal volunteers for research proto-
cols). In total, 219 subjects (70%) were found to have
significant CAD: 92 patients with single-vessel disease, 69
with two-vessel disease and 58 with three-vessel disease,
whereas 59 patients had no significant CAD. Per vessel,
there were 16 left main lesions, 162 left anterior descend-
ing lesions, 104 left circumflex and 128 right coronary
artery lesions. 309 subjects (99%) successfully completed
the infusion protocol (mean duration of infusion 231 ±
48 sec, see Table 1 for haemodynamic data). Patients on
beta-blockers showed a trend towards a diminished heart
rate response compared with beta-blocker-naïve subjects
from 11th Annual SCMR Scientific Sessions
Los Angeles, CA, USA. 1–3 February 2008
Published: 22 October 2008
Journal of Cardiovascular Magnetic Resonance 2008, 10(Suppl 1):A132 doi:10.1186/1532-429X-10-S1-A132
<supplement> <title> <p>Abstracts of the 11<sup>th </sup>Annual SCMR Scientific Sessions - 2008</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1532-429X-10-s1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1532-429X-10-S1-info.pdf</url> </supplement>
This abstract is available from: http://jcmr-online.com/content/10/S1/A132
© 2008 Karamitsos et al; licensee BioMed Central Ltd. Page 1 of 2
(page number not for citation purposes)
Journal of Cardiovascular Magnetic Resonance 2008, 10(Suppl 1):A132 http://jcmr-online.com/content/10/S1/A132Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
(19 ± 9 vs 21 ± 9 beats/min, p = 0.05). Importantly, there
were no deaths, myocardial infarctions, or episodes of
bronchospasm or pulmonary oedema. Transient AV node
block (2nd or 3rd degree) occurred in 25 patients (8%).
There were no sustained episodes of advanced AV block.
Chest pain was frequently reported (165 subjects – 53%)
but sublingual nitrate administration was needed in only
4 subjects (1%) after the infusion was stopped. Several
patients reported breathlessness (129 subjects – 41%) or
other vasodilator side-effects such as flushing, headache,
dizziness (126 subjects – 40%). However, all these symp-
toms resolved with termination of the infusion and no
aminophylline reversal was required.
Conclusion
In a large series, the use of intravenous adenosine in CMR
perfusion imaging is safe and well tolerated in patients
with even severe CAD. If a careful screening policy for con-
traindications to adenosine is followed, serious adverse
events in the CMR scanner are relatively rare and most
symptoms resolve following termination of the infusion
without the need for aminophylline.
Table 1: Haemodynamic data at rest and during adenosine infusion.
Rest Adenosine stress p-value
Heart rate (beats/min) 62 ± 11 81 ± 13 0.001
Systolic Blood Pressure (mmHg) 132 ± 18 129 ± 19 0.001
Diastolic Blood Pressure (mmHg) 76 ± 11 73 ± 12 0.001
Rate-Pressure Product (mmHg × beats/min) 8190 ± 2022 10451 ± 2554 0.001
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